- Services & Solutions
- Clients & Partners
Director, Cancer Immunology, Center for Cancer
Nathalie Scholler, M.D., Ph.D., studies the role of the immune system in cancer development. Scholler’s Laboratory focuses on the development of new strategies of prevention and immunotherapy of solid tumors. The Laboratory’s expertise includes development of model systems to address the role of immunity in solid tumor development and screening of yeast-display libraries of recombinant antibodies to identify antigen-specific targeting reagents
Cancer biomarkers are Scholler’s long time interest, beginning with the identification of Mesothelin as a soluble biomarker for ovarian cancer in 1999 and the development of the first mesothelin ELISA assay, now commercialized as MesomarkTM by Fujirebio, Inc. While a Senior Staff Scientist in Dr. Nicole Urban laboratory, FHCRC, WA, Scholler developed screening tools and recombinant antibodies for early detection of ovarian cancer using a yeast-display/secreted platform. Scholler’s laboratory at the University of Pennsylvania studied the role of innate immunity in ovarian cancer progression and developed targeted immunotherapies against cancer based on the functionalization of nanoparticles for organ-specific delivery of contrast imaging agents and/or cytotoxic reagents and on CAR T cell therapy. The National Cancer Institute, the National Institutes of Health, and the Department of Defense, as well as several private foundations, have funded Scholler’s research.
Scholler earned her M.D. degree from the School of Medicine of Marseille, France, and her Ph.D. in immunology from the University of Aix-Marseille II, France. She completed her post-doctoral training in the Autoimmunity Department of Bristol-Myers Squibb PRI in Seattle, WA. Scholler has authored or co-authored over 50 peer-reviewed publications, editorials, or book chapters, and has been a peer-reviewer for over 20 journals and for national and international grant study sections.